{
    "id": "dbpedia_6044_2",
    "rank": 51,
    "data": {
        "url": "https://tracxn.com/d/companies/sinopharm/__qJKiTQW_WsHhVeq1OPGdy9-7OZFCq8Jux8pvkXim2mg",
        "read_more_link": "",
        "language": "en",
        "title": "Company Profile",
        "top_image": "https://cdn.tracxn.com/images/seo/social/companies/sinopharm-overview-1708083640410.webp",
        "meta_img": "https://cdn.tracxn.com/images/seo/social/companies/sinopharm-overview-1708083640410.webp",
        "images": [
            "https://cdn.tracxn.com/images/static/tracxn-logo-full-100x22.svg",
            "https://i.tracxn.com/logo/company/32c74db41dcf5f94508c96cc5622efcb?height=120&width=120",
            "https://i.tracxn.com/logo/company/32c74db41dcf5f94508c96cc5622efcb?height=40&width=40",
            "https://i.tracxn.com/logo/company/JZL8w0fJ_400x400_1591330548086.jpg?height=40&width=40",
            "https://i.tracxn.com/logo/company/wrpvCVGq_400x400_399294dc-388c-4d74-a2ed-9d201444a868.png?height=40&width=40",
            "https://i.tracxn.com/logo/company/c5af719fefb9a22e7bcd969e8187f8?height=40&width=40",
            "https://i.tracxn.com/logo/company/proxima-ai.com_Logo_72b7685c-c6e7-4d3e-b959-c9f784f11120.jpg?height=30&width=30",
            "https://i.tracxn.com/logo/company/wiseltd.cn_Logo_e8aeaabe-b647-4273-9456-934cdb87f289.jpg?height=30&width=30",
            "https://i.tracxn.com/logo/company/Selection_049_1566908136365.png?height=30&width=30",
            "https://i.tracxn.com/tracxn-data-attachments/report/thumbnail/image/InfectiousDiseases_listing_image_22-10-2019_1571715989507_1580303505960_199e893b-5af7-4b4f-b53b-e832d4b87009.jpg?width=350"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Tracxn"
        ],
        "publish_date": "2022-07-06T04:16:26+00:00",
        "summary": "",
        "meta_description": "Sinopharm - Developer of vaccines for infectious diseases. Acquired by Nuance Pharma. Raised funding over 1 round from 3 investors. Founded by Mahmoud Aziz and Lee Leonardo in the year 2009. Sinopharm has 373 competitors.",
        "meta_lang": "en",
        "meta_favicon": "https://cdn.tracxn.com/images/static/favicon.ico",
        "meta_site_name": "",
        "canonical_link": "https://tracxn.com/d/companies/sinopharm/__qJKiTQW_WsHhVeq1OPGdy9-7OZFCq8Jux8pvkXim2mg",
        "text": "Sinopharm company profile\n\nDeveloper of vaccines for infectious diseases\n\n2009•Beijing ( China )•Acquired\n\nSinopharm Key Metrics\n\nLatest Funding Round\n\nUndisclosed\n\nSeries A, Dec 04, 2015\n\nInvestors\n\n6 Dimensions Capital\n\n& 2 more\n\nRanked\n\n41st\n\namong 310 active competitors\n\nInvestment & Acquisitions\n\nXingmai Technology\n\n& 3 more\n\nSimilar Companies\n\nModerna\n\n& 345 more\n\nExit Details\n\nAcquired\n\nby Nuance Pharma (Jan 06, 2022)\n\nSinopharm - About the company\n\nWhat does Sinopharm do?\n\nDeveloper of vaccines for infectious diseases. The company's lead product is the enterovirus vaccine (EV71 inactivated vaccine) to reduce the incidence of hand, foot, and mouth disease in children. It has R & D for polio vaccines, COVID-19 and pneumonia. Also, it develops in vitro diagnostic kits, medical consumables, medical protective materials, smart wearables equipment, and other product lines.\n\nWhich sectors and market segments does Sinopharm operate in?\n\nSinopharm serves in the B2B space in the Life Sciences, Sustainability Tech market segments.\n\nThe primary business model of Sinopharm are :Life Sciences > Infectious Diseases > ***** **** > ***** ******Sustainability Tech > Infectious Diseases > ***** **** > ***** ******\n\nSinopharm's acquisition details\n\nSinopharm got acquired by Nuance Pharma on Jan 06, 2022.\n\nClick here to take a look at Sinopharm 's acquisition in detail\n\nSinopharm's funding and investors\n\nHow much funding has Sinopharm raised till date?\n\nSinopharm has raised funding over 1 round.\n\nList of recent funding rounds of Sinopharm\n\nDate of funding\n\nFunding Amount\n\nRound Name\n\nPost money valuation\n\nRevenue multiple\n\nInvestors\n\nDec 04, 2015\n\nUndisclosed\n\nSeries A\n\n5128792\n\n9718000\n\n-\n\nAccess funding benchmarks and valuations. Sign up today!\n\nWho are Sinopharm's investors?\n\nSinopharm has 3 institutional investor s including 6 Dimensions Capital, Frontline BioVentures and Alpview Capital.\n\nView details of Sinopharm funding rounds and investors\n\nSinopharm's founders and board of directors\n\nFounder? Claim Profile\n\nWho are the founders of Sinopharm?\n\nThe founders of Sinopharm are Mahmoud Aziz and Lee Leonardo.\n\nWho is the current CEO of Sinopharm?\n\nMahmoud Aziz is the CEO of Sinopharm .\n\nSinopharm's Competitors and alternates\n\nWho are the competitors of Sinopharm?\n\nTop competitor s of Sinopharm include Moderna, Adaptive Biotechnologies and Dynavax.\n\nSinopharm ranks 41 st among 310 active competitors. 95 of its competitors are funded while 71 have exited. Overall, Sinopharm and its competitors have raised over $10.6B in funding across 382 funding rounds involving 808 investors. There is 1 private unicorn, 46 public and 25 acquired companies in the entire competition set.\n\nBelow is a comparison of top competitors of Sinopharm\n\nSinopharm\n\nDescription\n\nDeveloper of vaccines for infectious diseases\n\nDeveloper of mRNA-based therapeutics for a wide range of diseases\n\nProvider of clinical diagnostics, and drug discovery for immune diseases\n\nDeveloper of products to prevent and treat infectious and inflammatory diseases and cancer\n\nFounded Year\n\n2009\n\n2010\n\n2009\n\n1996\n\nLocation\n\nBeijing (China)\n\nCambridge (United States)\n\nSeattle (United States)\n\nBerkeley (United States)\n\nCompany Stage\n\nAcquired\n\nPublic\n\nPublic\n\nPublic\n\nUnicorn Rating\n\n-\n\n-\n\n-\n\n-\n\nTotal Funding\n\n-\n\n$2.78B\n\n$419M\n\n$73.9M\n\nFunding Rounds\n\n1\n\n17\n\n11\n\n9\n\nLatest Round\n\nSeries A, Undisclosed, Dec 04, 2015\n\nGrant (prize money), $56M, Oct 08, 2020\n\nSeries F, Undisclosed, Jan 22, 2018\n\nPost IPO, Undisclosed, Aug 27, 2021\n\nInvestor Count\n\n3\n\n30\n\n22\n\n25\n\nTop Investors\n\nTracxn Score What is this?\n\n52/100\n\n79/100\n\n75/100\n\n70/100\n\nOverall Rank\n\n41st\n\n1st\n\n2nd\n\n3rd\n\nGet insights and benchmarks for competitors of 2M+ companies! Sign up today!\n\nLooking for more details on Sinopharm 's competitors? Click here to see the top ones\n\nSinopharm's Investments and acquisitions\n\nFilter this list\n\nSinopharm has not made any acquisitions yet. Sinopharm has made 4 investments. Here is the list of latest three investments:\n\nDate of Investment/Acquisition\n\nType\n\nCompany Name\n\nFounded Year\n\nLocation\n\nAug 03, 2022\n\nInvestments\n\n2017\n\nShanghai, China\n\nApr 26, 2022\n\nInvestments\n\n2016\n\nBeijing, China\n\nMar 03, 2022\n\nInvestments\n\n2018\n\nHaidian, China\n\nWant to know more about where corporates are investing? Sign up today!\n\nSee all investments by Sinopharm\n\nReports related to Sinopharm\n\nHere is the latest report on Sinopharm's sector:\n\nFree\n\nInfectious Diseases - Sector Report\n\nEdition: Jul 12, 2024 (77 Pages)\n\nNews related to Sinopharm\n\nFilter this list\n\nMedia has covered Sinopharm for 1 event in last 1 year , It was about partnerships .\n\n•\n\nPfizer signs strategic cooperation pact with China's SinopharmZawya•Apr 13, 2023•Sinopharm , Pfizer\n\n•\n\nSinopharm partners with Elekta to bring radiation therapy across ChinaChina Daily•Mar 23, 2023•Sinopharm , Elekta\n\n•\n\nElekta forms radiotherapy partnership with Sinopharm in ChinaMassDevice•Mar 14, 2023•Elekta, Sinopharm\n\n•\n\nGE HealthCare and Sinopharm to form joint venture in ChinaSeeking Alpha•Feb 24, 2023•GE Healthcare, Sinopharm\n\nGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!\n\nView more Sinopharm Recent News\n\nFrequently asked questions about Sinopharm\n\nWhen was Sinopharm founded?\n\nSinopharm was founded in 2009.\n\nWhere is Sinopharm located?\n\nSinopharm is located in Beijing, China.\n\nIs Sinopharm an acquired company?\n\nSinopharm got acquired by Nuance Pharma on Jan 06, 2022.\n\nWhen was the latest funding round of Sinopharm?\n\nSinopharm's latest funding round was on Dec 04, 2015.\n\nIs Sinopharm a Infectious Diseases company?\n\nThe primary sector of Sinopharm is Infectious Diseases."
    }
}